Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center

Shamir Geller*, Emily Lebowitz, Melissa P. Pulitzer, Steven M. Horwitz, Alison J. Moskowitz, Steve Dusza, Patricia L. Myskowski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients. Objective: To describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS. Methods: Clinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018. Results: We included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P =.002) and progression-free survival (P =.014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis. Limitations: A retrospective study at a single cancer center. Conclusion: MF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions.

Original languageEnglish
Pages (from-to)430-439
Number of pages10
JournalJournal of the American Academy of Dermatology
Volume83
Issue number2
DOIs
StatePublished - Aug 2020
Externally publishedYes

Funding

FundersFunder number
ADC Therapeutics
ADCT Therapeutics
Celgene and Trillium
Kyowa Hakko Kirin Pharma
Miragen Therapeutics
Syros Pharmaceutical
National Institutes of Health
National Cancer InstituteP30CA008748
Merck
Takeda Pharmaceutical Company

    Keywords

    • African American
    • MF
    • cutaneous lymphoma
    • hyperpigmented MF
    • hypopigmented MF
    • racial disparity
    • skin of color
    • survival analysis

    Fingerprint

    Dive into the research topics of 'Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center'. Together they form a unique fingerprint.

    Cite this